Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1723 - Impact of depth of response (DpR) on survival in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line panitumumab + FOLFOX4 vs FOLFOX4


08 Oct 2016


Poster Display


Salvatore Siena


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


S. Siena1, F. Rivera Herrero2, J. Douillard3, J. Taieb4, R. Koukakis5, G. Demonty6, M. Peeters7

Author affiliations

  • 1 Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano, 20162 - Milano/IT
  • 2 Medical Oncology, University Hospital Marques de Valdecilla, Santander/ES
  • 3 Oncologie Médicale, ICO R. Gauducheau, 44805 - St Herblain/FR
  • 4 Department Of Gastroenterology And Digestive Oncology, Hôpital Européen Georges Pompidou, 75015 - Paris/FR
  • 5 Biostatistics, Amgen Ltd, Uxbridge/GB
  • 6 Medical Development - Oncology, Amgen (Europe) GmbH, Zug/CH
  • 7 Department Of Oncology, University Hospital Antwerp, 2650 - Edegem/BE


Abstract 1723


DpR has been associated with overall survival (OS) in first-line trials of epidermal growth factor receptor inhibitors + chemotherapy in pts with mCRC. Here we evaluate the impact of DpR on progression-free survival (PFS) and OS in pts with RAS WT mCRC from the PRIME trial.


PRIME (NCT00364013) was a randomised, phase III trial of first-line panitumumumab + FOLFOX4 vs FOLFOX4 in pts with mCRC. DpR was calculated as the maximal % change from baseline to nadir in pts who had tumour shrinkage. In pts with tumour growth, DpR was defined as


Overall, 460 pts with RAS   WT mCRC who had measurable disease at baseline and calculable DpR post-baseline, were included in the analysis. Median DpR was higher in pts receiving panitumumab + FOLFOX4 vs FOLFOX4 (54% vs 46%; p = 0.0149). In the simple regression model, DpR was associated with PFS (p 


These exploratory analyses from PRIME suggest that deeper responses are significantly associated with longer OS and PFS in pts with RAS WT mCRC.

Clinical trial identification


Legal entity responsible for the study



Amgen (Europe) GmbH


S. Siena: Member of advisory boards or steering committees or principal investigator for Amgen, Bayer, Boehringer Ingelheim, Celgene, Genentech, Ignyta, Merck, Merrimack, Novartis, Pfzer, Roche, and SanofiAventis. F. Rivera Herrero: Acted on advisory boards and received research funding from Amgen, Sanofi, Merck-Serono and Roche. J-Y. Douillard: Honoraria/travel/accommodation/expenses while performing consulting/advisory roles for Amgen, Bayer, Roche and Merck and has also received research funding from Merck Serono. J. Taieb: Honoraria/consulting/advisory role for Roche, Amgen, Merck, Lilly, Sanofi, Celgene, Sirtex R. Koukakis: Employee of Amgen Ltd and stockowner. G. Demonty: Employee of Amgen (Europe) GmbH and stockholder. M. Peeters: Received research funding and acted in consultancy/advisory roles for Amgen and received research funding and participated in symposia for Merck Serono.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings